Humalog ® (insulin lispro)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Humalog Summary of Product Characteristics (SmPC)

Humalog Mix25/Mix50 (insulin lispro): Posology and method of administration

The dosage should be determined by the physician, according to the requirement of the patient

Posology

The dosage should be determined by the physician, according to the requirement of the patient.

Humalog Mix25 and Humalog Mix50 may be given shortly before meals. When necessary, Humalog Mix25 and Humalog Mix50 can be given soon after meals. Humalog Mix25 and Humalog Mix50 should only be given by subcutaneous injection. Under no circumstances should Humalog Mix25 or Humalog Mix50 be given intravenously.

The rapid onset and early peak of activity of Humalog itself is observed following the subcutaneous administration of Humalog Mix25 and Humalog Mix50. This allows Humalog Mix25 and Humalog Mix50 to be given very close to mealtime. The duration of action of the insulin lispro protamine suspension component of Humalog Mix25 and Humalog Mix50 is similar to that of a basal insulin (NPH [isophane]).

The time course of action of any insulin may vary considerably in different individuals or at different times in the same individual. As with all insulin preparations, the duration of action of Humalog Mix25 and Humalog Mix50 is dependent on dose, site of injection, blood supply, temperature, and physical activity.

Special populations

Renal impairment

Insulin requirements may be reduced in the presence of renal impairment.

Hepatic impairment

Insulin requirements may be reduced in patients with hepatic impairment due to reduced capacity for gluconeogenesis and reduced insulin breakdown; however, in patients with chronic hepatic impairment, an increase in insulin resistance may lead to increased insulin requirements.

Paediatric population

Administration of Humalog Mix25 or Humalog Mix50 to children below 12 years of age should be considered only in case of an expected benefit when compared to soluble insulin.

Method of administration

Subcutaneous administration should be in the upper arms, thighs, buttocks, or abdomen. Use of injection sites should be rotated so that the same site is not used more than approximately once a month.

When administered subcutaneously care should be taken when injecting Humalog Mix25 or Humalog Mix50 to ensure that a blood vessel has not been entered. After injection, the site of injection should not be massaged. Patients must be educated to use the proper injection techniques.

KwikPen

The KwikPen delivers 1 – 60 units in steps of 1 unit in a single injection. The needed dose is dialled in units. The number of units is shown in the dose window of the pen.

Reference

Humalog Mix 25 [Summary of Product Characteristics]. Utrecht, The Netherlands: Eli Lilly Nederland B.V.

Humalog Mix 50 [Summary of Product Characteristics]. Utrecht, The Netherlands: Eli Lilly Nederland B.V.

Date of Last Review: January 10, 2019

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question